MedTrace Logo

BOTOX® Prophylaxis in Patients With Chronic Migraine

NCT01432379 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1168

Last updated 2019-01-08

Study results available
· View outcomes & findings →

Summary

This is a post authorization observational study to monitor the utilization practices and describe the safety profile of BOTOX® in clinical practice for the prophylactic treatment of headaches in adult patients with chronic migraine.

Conditions

  • Migraine Disorders

Interventions

BIOLOGICAL

botulinum toxin Type A

155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-09
Primary Completion
2015-05-12
Completion
2015-05-12

Countries

  • Germany
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01432379 on ClinicalTrials.gov